/

ALPMF

Astellas Pharma, Inc.After hours

13.10−2.20 −14.38%USD

OTC Markets OTCPK · as of Oct 13, 16:00 ET · 15m delay

Open

15.00

Prev close

15.30

Day range

15.0015.00

52-week range

9.8517.85

Volume

3410.06×

Mkt cap

23.49B

P/E ttm

9.92

Fwd P/E

29.77

EPS ttm

1.32

Div yield

3.85%

Earnings

Nov 4, 2026

From 52w high

−26.61%

Price Chart

Yahoo Finance · delayed

ALPMFOct 13, 2026O 13.10H 13.10L 13.10C 13.10−2.20 (−14.38%)Vol 300

SMA 5015.09
SMA 20014.82

1Y change +22.09% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ALPMF Astellas Pharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −14.66%
1 month: −17.35%
3 months: +1.95%
6 months: −20.75%
Year to date: −0.53%
1 year: +22.09%

Valuation & ownership

Market cap: 23.49B
Enterprise value: 370.42B
P/E (ttm): 9.92
Forward P/E: 29.77
PEG ratio: —
Price / book: 1.91
Price / sales (ttm): 0.01
EV / EBITDA: 0.55
EPS (ttm): 1.32
EPS (forward): 0.4400
Beta (5y monthly): 0.09
Dividend yield: 3.85%
Payout ratio: 38.41%
Shares outstanding: 1.79B
Float: 1.79B
Short % of float: —
Short ratio (days): —
Held by insiders: 0.08%
Held by institutions: 62.37%
Avg volume (3m): 5.87K
50-day average: 15.09
200-day average: 14.82
52-week change: +22.09%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 40.1
vs 50-day SMA: −13.17%
vs 200-day SMA: −11.58%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.75%
Realised vol (20d, ann.): 105.7%
From 52-week high: −26.61%
From 52-week low: +32.99%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 2.27T
Revenue growth (yoy): +26.70%
Earnings growth (yoy): +107.20%
Gross margin: 80.82%
Operating margin: 28.92%
Profit margin: 16.05%

DES

About Astellas Pharma, Inc.

Yahoo Finance profile

Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.

Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 14,099
Headquarters: Chuo, Japan
Website: astellas.com
Officers: Mr. Naoki Okamura BSc President, CEO & Representative Director
Mr. Katsuyoshi Sugita Executive VP, Chief People Officer & Representative Director
Mr. Atsushi Kitamura Chief Financial Officer

SEAS

Seasonality · ALPMF

2010–2026 · monthly returns

Strongest month Jun +3.50%Weakest month Apr −1.98%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	3.8	21.1	-2.4	-11.7	7.6	-5.5	1.7	7.8	-7.7	-10.7			−0.5%
2025	-4.9	6.6	-2.5	3.8	-7.5	2.7	8.8	9.8	-3.3	-0.3	10.5	7.7	+33.6%
2024	0.5	-8.4	1.2	-14.8	2.6	-3.5	11.9	15.7	-8.3	-0.6	1.2	-12.4	−17.8%
2023	-3.5	-8.1	3.3	4.0	6.1	-6.6	2.4	1.4	-8.6	-8.0	-8.3	1.9	−23.0%
2022	0.4	4.5	-7.7	2.0	-1.6	7.5	-9.2	-7.8	-8.8	10.3	7.7	2.7	−2.6%
2021	8.4	-5.5	-1.0	-3.2	6.2	7.6	-7.8	4.5	-2.1	1.5	-5.6	3.3	+4.7%
2020	1.3	-12.0	4.1	1.8	-4.1	9.6	-6.2	-3.3	-3.4	-8.2	3.4	7.7	−10.9%
2019	8.2	6.8	-1.9	-9.2	-0.5	3.4	4.2	-6.1	6.0	18.6	-1.1	2.6	+32.1%
2018	4.9	10.7	3.9	-4.7	10.6	-5.2	6.4	5.9	3.6	-15.1	-4.5	-9.8	+3.0%
2017	-4.6	0.1	-2.8	-2.1	-2.1	-2.7	1.4	0.8	2.6	3.9	-5.0	-1.9	−12.1%
2016	3.2	-1.0	-8.8	9.9	-8.1	22.5	-0.2	-6.4	4.9	-4.7	-6.0	0.0	+1.3%
2015	10.3	3.7	7.1	-4.6	-8.4	-1.2	0.3	-4.9	-5.7	7.3	1.0	0.8	+3.7%
2014	1.7	5.2	-4.7	-9.4	21.2	1.2	4.6	6.2	1.3	2.9	-5.0	-4.5	+19.0%
2013	12.1	5.4	0.3	3.2	-8.4	2.0	5.8	-5.9	-2.7	9.2	6.7	-2.9	+25.4%
2012	1.0	0.2	1.3	-3.8	-2.5	12.0	9.2	2.1	4.3	-2.0	1.5	-9.1	+13.5%
2011	3.5	2.8	-2.9	-2.6	2.0	2.3	0.6	-4.4	2.2	-2.9	2.6	6.9	+9.7%
2010					-4.8	4.5	-0.7	2.7	5.1	2.7	-3.3	1.5	+7.3%

ALPMF

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ALPMF

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Astellas Pharma, Inc.

Seasonality · ALPMF

Insider Activity · ALPMF

Congress Trades · ALPMF

Investors Holding ALPMF

Investors Holding ALPMF

Congress Trades · ALPMF

Insider Activity · ALPMF

Seasonality · ALPMF

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Astellas Pharma, Inc.

Earnings & Dividends

News